无症状转移性食管胃癌一线姑息性系统治疗启动的最佳时机:一项欧洲德尔菲研究的见解
这项欧洲德尔菲研究通过两轮在线调查(第一轮39名、第二轮33名医生)评估了无症状转移性食管胃癌患者启动一线姑息性系统治疗的最佳时机。结果显示,12个(86%)场景达成共识立即启动治疗;仅2个场景(既往WHO/ECOG 2分或78岁)达成共识可延迟治疗。
要点
- 无症状转移性食管胃癌患者,欧洲专家共识倾向于立即启动姑息性系统治疗(12/14场景,86%达成共识)。
- 若患者倾向延迟且医生认为合理,半数场景(7个)仍共识建议立即启动治疗。
- 仅当患者既往WHO/ECOG 2分或年龄78岁时,共识认为可延迟治疗。
核心结论
- 在无症状转移性食管胃癌中,欧洲专家倾向于立即启动治疗;对于倾向延迟且既往WHO/ECOG 2分或高龄的患者,共识认为可延迟治疗。
研究设计与样本
- 德尔菲研究:在线调查包含14个场景,医生选择立即(<3周)或延迟启动系统治疗;标准场景为65岁男性、WHO/ECOG 0、无症状转移性食管胃癌、双肺各2个转移灶、HER2阴性、PDL1-CPS 2,每个后续场景修改一个特征;共识定义为≥75%同意,未达成共识的场景在第二轮重新评估;第一轮39名医生参与,第二轮33名。
主要发现
- 12个(86%)场景达成共识立即启动治疗。
- 当患者倾向延迟时,半数场景(n=7)共识仍建议立即启动姑息性系统治疗。
- 仅2个场景(既往WHO/ECOG 2分或78岁)达成共识可延迟治疗。
关键数值与推荐
- 共识定义为≥75%同意。
- 立即启动定义为<3周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The enhanced application of imaging techniques is resulting in the diagnosis of more patients with asymptomatic metastatic esophagogastric cancer (mEGC). We conducted a Delphi study to gather insights from European experts on the optimal timing for initiating palliative systemic therapy for these patients. METHODS: An online survey featured 14 scenarios where physicians chose their preferred timing for initiating systemic therapy: immediate(<3 weeks) or deferred. The standard scenario was a 65-year-old male, WHO/ECOG 0 with asymptomatic mEGC, 2 metastases in each lung, HER2 -, PDL1-CPS 2. In every subsequent case, one characteristic was modified. To investigate the fortitude of the physicians' preference for an immediate start, scenarios also included a patient who was motivated to start but preferred to defer if the physician deemed it judicious. Consensus was defined as ≥ 75 % agreement; scenarios without consensus were re-evaluated in Delphi round 2. RESULTS: Thirty-nine physicians participated in the first round, and 33 in the second round. Consensus to start treatment immediately was reached in 12 (86 %) scenarios. When patients preferred to defer, the consensus was to still advise to start palliative systemic treatment immediately in half (n = 7) of the scenarios. Only 2 scenarios (pre-existent WHO/ECOG 2 or 78 years old) reached the consensus that treatment could be deferred. CONCLUSIONS: In asymptomatic mEGC, immediate start of treatment is preferred by European experts. Consensus was established that treatment can be deferred for patients who prefer deferral and either have a pre-existent WHO/ECOG performance status of 2 or are of advanced age.
引用
- Kamp D, May AM, Adenis A, et al. Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study. Eur J Cancer. 2025. PMID: 39919335. doi:10.1016/j.ejca.2025.115278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。